LEADER trial: difference between revisions
Diff·revision 11 → 12·23:45, 16 Feb 2025
Difference between revision 11 and revision 12 of LEADER trial. 2 lines changed; the page grew by 260 bytes.
| Revision 11 — 14:19, 24 Jan 2025 StubSorterBot (talk) bot: sort category members 3,277 bytes +99 | Revision 12 — 23:45, 16 Feb 2025 SurmountSurma (talk) rm a duplicated category 3,537 bytes +260 | ||
|---|---|---|---|
| 31 | The renal signal in LEADER was a pre-specified secondary outcome and was driven principally by new-onset persistent macroalbuminuria, a marker rather than a hard endpoint. The dedicated renal question was subsequently addressed by [[FLOW trial|FLOW]] with a different agent and a composite of harder outcomes.{{r|perkovic2024}} | 31 | The renal signal in LEADER was a pre-specified secondary outcome and was driven principally by new-onset persistent macroalbuminuria, a marker rather than a hard endpoint. The dedicated renal question was subsequently addressed by [[FLOW trial|FLOW]] with a different agent and a composite of harder outcomes.{{r|perkovic2024}} |
| 32 | 32 | ||
| + | 33 | Glycated haemoglobin was about 0.4 percentage points lower on liraglutide, and weight about 2.3 kg lower. Both differences are modest and are part of why the mechanism of the cardiovascular benefit is not attributed to glycaemic control alone.{{r|marso2016}} | |
| + | 34 | ||
| 33 | == References == | 35 | == References == |
| 34 | {{reflist}} | 36 | {{reflist}} |